MuGard® Oral Mucoadhesive provides effective management of oral mucositis (OM)1

MuGard has been shown to reduce the incidence and severity of oral mucositis, delay the onset of treatment-induced mouth sores, help patients better maintain weight during cancer treatment, and use less pain management medications. MuGard was evaluated in several studies including a multicenter, randomized, double-blind, controlled trial1

To download this study for MuGard, please click here.

Study design

Multicentered, randomized, double-blind, controlled trial in patients being treated with chemoradiation for cancers of the head and neck1

MuGard study result
  • Conventional course of external beam irradiation (single daily fractions of 2.0 Gy to 2.2 Gy) with a cumulative dose of 50 Gy to 72 Gy1
  • Concomitant cisplatin was administered weekly or triweekly1
* Flavored saline bicarbonate rinse indistinguishable from MuGard in appearance and identically bottled and labeled.1

Primary efficacy end point

Assessment of the reduction in patients’ mouth and throat soreness associated with OM.1 Significant mouth and throat soreness measured by patient-reported Oral Mucositis Daily Questionnaire (OMDQ) mouth and throat soreness question 2 scores of > 2 was previously described to align with severe mucositis.1

OMDQ mouth and throat soreness question 23

MuGard question 2 responses

Gives you the confidence of proven efficacy1

In a clinical trial, MuGard significantly reduced mouth and throat soreness compared with saline bicarbonate rinse (control)1,4,a

MuGard efficacy study

In a controlled clinical trial of MuGard, no significant adverse events were reported1

The overall incidence of unanticipated adverse device effects was similar in the MuGard (8%) and control (12%) groups.1
  • No patients discontinued MuGard because of unanticipated adverse device effects; however, 2 subjects in the saline bicarbonate rinse group discontinued due to nausea or vomiting1

Indication and Important Safety Information

Indication: MuGard® Oral Mucoadhesive is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Contraindications: MuGard is contraindicated in patients with known hypersensitivity to any of the ingredients in the formulation.

Special Precautions for Use: Patients should avoid eating or drinking for at least one hour after using MuGard. After use, patients should replace the bottle cap and tightly seal the bottle. This product should not be used after the expiration date shown on the carton and product label. Do not use this product in patients with known sensitivity to any of the product’s ingredients. Dilution of the product prior to use is not recommended.

You may report a MuGard® adverse event to Soleva Pharma at 877-319-7272 or by emailing to

Please see accompanying full Prescribing Information.